PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Investors

Press Releases

General Releases
View Summary BioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular Dystrophy to Understand Their Genetic Mutation
Sep 1, 2015
PDF 11.6 KB Add to Briefcase
View Summary BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
Aug 31, 2015
PDF 64.6 KB Add to Briefcase
View Summary Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
Aug 24, 2015
PDF 13.0 KB Add to Briefcase
View Summary BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy
Aug 19, 2015
PDF 10.0 KB Add to Briefcase
View Summary Forbes Ranks BioMarin 10th Most Innovative Company in the World
Aug 19, 2015
PDF 9.6 KB Add to Briefcase
View Summary BioMarin Announces Second Quarter 2015 Financial Results and Company Update
Aug 3, 2015
PDF 53.1 KB Add to Briefcase
View Summary BioMarin Joins the NASDAQ-100 Index
Jul 27, 2015
PDF 9.0 KB Add to Briefcase
View Summary BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Jul 20, 2015
PDF 13.6 KB Add to Briefcase
View Summary BioMarin to Host Second Quarter 2015 Financial Results Conference Call and Webcast on Monday, August 3 at 4:30pm ET
Jul 15, 2015
PDF 8.8 KB Add to Briefcase
View Summary BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Jun 29, 2015
PDF 11.7 KB Add to Briefcase
View Summary BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Jun 25, 2015
PDF 11.3 KB Add to Briefcase
View Summary BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
Jun 17, 2015
PDF 18.2 KB Add to Briefcase
View Summary BioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health and Life Sciences
Jun 15, 2015
PDF 10.5 KB Add to Briefcase
View Summary BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Jun 8, 2015
PDF 11.3 KB Add to Briefcase
View Summary Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
Jun 4, 2015
PDF 7.8 KB Add to Briefcase
View Summary BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th
May 1, 2015
PDF 8.6 KB Add to Briefcase
View Summary BioMarin Announces First Quarter 2015 Financial Results and Company Update
Apr 30, 2015
PDF 32.8 KB Add to Briefcase
View Summary BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Apr 27, 2015
PDF 11.3 KB Add to Briefcase
View Summary BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
Apr 23, 2015
PDF 13.9 KB Add to Briefcase
View Summary BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 21, 2015
PDF 9.6 KB Add to Briefcase
Showing 1-20 of 221 Page: 1 2 3 4 5 ... 12  Next 20
Add to Briefcase = add release to Briefcase